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Preface 
 
 
Cancer continues to be a worldwide killer; there are more than 20 different types 
of cancer. In 2008 approximately 12.7 million cancers were diagnosed [1] and in 
2010 nearly 7.98 million people died [2]. Cancer can develop from almost any type of 
cell in the body. Cancers as a group account for approximately 13% of all deaths 
each year with the most common being: lung cancer (1.4 million deaths), stomach 
cancer (740,000 deaths), liver cancer (700,000 deaths), colorectal cancer (610,000 
deaths), and breast cancer (460,000 deaths) [3]. Cancer is caused by both internal 
factors such as inherited mutations, hormones, and immune conditions and 
environmental/acquired factors such as tobacco, diet, radiation, and infectious 
organisms; This makes invasive cancer the leading cause of death in the developed 
world and the second leading cause of death in the developing world [1,3]. 
Malignant mesothelioma (MM), is an aggressive, treatment-resistant tumor, which 
is increasing in frequency throughout the world [4]. Moreover, although MM is still 
a rare cancer, its incidence is increasing in many countries [5–8]. From 1994 to 2008 
the 15-year magnitude of mesothelioma is estimated to be 174,300 in a group of 56 
countries that report the disease, and 38,900 for the same 15-year period by 
extrapolation to a group of 33 countries that do not systematically report the 
disease [9]. Key changes that occur during the development of the disease include 
the loss of the normal restraints on proliferation and the acquisition of resistance to 
apoptosis, and asbestos, a complete carcinogen for mesothelial cells, plays a complex 
role in altering both proliferation and apoptosis [10].  
MM patients have a history of asbestos exposure. Asbestos refers to a family of six 
mineral fibers and is classified into two subgroups: (i) the amphiboles, a group of 
rod-like fibers including amosite (brown asbestos), crocidolite (blue asbestos), 
anthophyllite, actinolite and tremolite; (ii) the serpentine group, consisting of 
chrysotile (white asbestos) [11], which promotes difficult disease 30-40 years after 
the exposure [12]. There is a direct causal relationship between asbestos exposure 
and the development of mesothelioma, with an etiological fraction of 80% or more 
[4]. And several mechanisms might account for this finding that the asbestos fibers 
stick out from the lung surface and cause repeated cycles of scratching, damage, 
inflammation, and repair in the adjacent parietal mesothelial cell layer [13]. 
  Although the association between MM and asbestos is well established, other 
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carcinogenic factors must be involved in MM development because only 10% of all 
MM cases occur in asbestos exposed subjects [14]. Simian virus 40 (SV40), a DNA 
virus, has been implicated in the development of several cancers including MM [15]. 
That report showed that SV40 oncogenes could lead to malignant transformation of 
mesothelial cells and used an in vitro mouse model mesothelial cells which were 
more susceptible to asbestos induced apoptosis than normal mesothelial cells [15]. 
However, the putative involvement of SV40 in the pathogenesis of MM has become 
a controversial issue, and its role remains unclear and unproved [13]. One study 
showed that long-term exposure (100 days) to both SV40 and asbestos, primary 
peritoneal mouse mesothelioma cells become resistant to stress induced senescence 
[15]. On the other hand, occur by silencing promoter of the Cdk inhibitor p21 (p21) 
through p53 inactivation by SV40 proteins and/or the weaker activation of p21 by 
alternative pathways [16]. A greater reduction in p21 expression will cause greater 
aggression and result in a poorer prognosis of human mesothelioma [16]. Therefore, 
new therapeutic approaches are urgently needed for MM patients. 
The anti-folate pemetrexed was the first licensed drug in combination with 
cisplatin (CDDP) for malignant mesothelioma. Results were presented at the 
Society of Clinical Oncology and the European Crohn’s and Colitis Organization in 
2007 [12]. Pemetrexed is a potent inhibitor of thymidylate synthase, which is 
required for DNA synthesis. A multicentre phase Ⅲ  study in 448 patients 
compared this drug combination with CDDP alone, and showed an improvement in 
overall survival of nearly 3 months with the combination, with an objective 
response rate of 41% [4]. The addition of folic acid and vitamin B12 supplementation 
resulted in a significant reduction in pemetrexed related toxicity. Thus, pemetrexed 
and CDDP is likely to be used widely as first-line chemotherapy for MM [17]. 
Vitamin E administration is an attractive alternative therapy for cancer patients. 
Since the discovery of this fat-soluble vitamin in 1922, many studies have focused 
on the potential health benefits and therapeutic use of α-, β-, δ- and γ-tocopherol 
[18,19]. Similarly, γ-tocotrienol (γ-T3) (Fig.A), another isoform of vitamin E, induces 
apoptosis in a variety of cancer cell types [20,21]. Additionally, γ-T3 has gained 
much interest owing to its lipid-lowering effects in cell-based studies and especially 
for its ability to lower cholesterol by inhibiting 3-hydroxymethyl-3-methylglutaryl 
coenzyme A reductase (HMGR) [22]. Compared to other vitamin E isomers, γ-T3 
has superiorperior abilities in anticancer, neuroprotective and cholesterol-lowering 
activities [23,24]. Most recently, γ-T3 has exhibited anticancer activity in numerous 
human cancers, including prostate [25], breast [26], colon [27], liver [28] cancers. 
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Statins are currently some of the most widely used pharmaceutical agents in the 
world [29,30] which include atorvastatin (Fig.B), simvastatin (Fig.C), lovastatin, 
and pravastatin. Their main function is to inhibit the endogenous synthesis of 
cholesterol [29]; in addition to that, they appear to have pleiotropic effects such as 
modulation of cell growth, apoptosis, and inflammation [31]. Statins are competitive 
inhibitors of HMGR, which has been found to directly block tumor cell growth both 
in vitro and in vivo [32], thus making it a unique molecular target for anticancer 
therapy. Furthermore, statins have been found to induce apoptosis [33]. In most 
clinical studies, the debate has centered on whether the use of statins causes 
cognitive decline, diabetes mellitus [34], or cancers such as prostate [33], breast [35], 
colorectal [31], liver [29], and pancreatic tumors [36]. Thus statins are attractive 
therapeutic compounds for life style diseases, however, high concentration of statins 
would induce severe side-effect. Clinical trials with prostate, breast, colorectal, 
ovarian, and lung cancer patients determined that high-dose treatment was 
associated with severe myopathy with the maximum dose of lovastatin that could be 
tolerated to be 25 mg/kg, which produced a peak plasma concentration of 3.9 μM 
[37]. Since the dose of lovastatin required to inhibit growth and apoptosis of cancer 
cells in culture ranged between 0.1 and 100 μM, toxic doses of lovastatin must be 
used to effectively treat cancer patients. Moreover, to be achieved apoptosis of 
cancer cells, more than several tens μM of lovastatins was required. Therefore it 
limits clinical use of statins though they possess strong anticancer effects.  
The endoplasmic reticulum (ER) is an essential intracellular organelle with 
multiple roles including the synthesis of nascent proteins, Ca2+ storage, 
glycosylation, and the trafficking of newly-synthesized membrane and secretory 
proteins. Perturbations of these processes have been demonstrated to interfere with 
the proper functioning of ER, thus leading to a condition defined as ER stress [38]. 
Inadequate supplies of glucose affect the glycosylation of secretory pathway 
proteins and ATP production, both of which lead to the accumulation of unfolded 
proteins in the ER, resulting in ER stress [39]. The tumor microenvironment is 
characterized by poor vascularization, low oxygen supply, and nutrient deprivation 
all of which are activators of ER stress. In rapidly growing cancers, unfolded protein 
response (UPR) has been shown to exert an important cytoprotective role that 
assists folding of newly synthesized proteins necessary for tumor growth [40]. These 
integrated mechanisms, although they may reflect tumor cell specificities related to 
their metabolism or proliferation ability, could represent interesting avenue for 
therapeutic strategy as their inhibition/activation would prevent tumor cell 
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adaptation to environmental challenges [41]. 
Thus, combination chemotherapy could optimize the effectiveness of each drug by 
inciting a complimentary and synergetic therapeutic response while concurrently 
reducing toxic adverse side effects associated with high-dose single-agent therapy. 
In this context, the present study for the first time investigates the possible 
synergistic effects of γ-T3 in combination with statin in human MM cell lines. As 
estimated molecular targets, we concentrated on HMGR expression and the 
following signaling (common targets of γ-T3 and statins), ER stress markers 
(targets of γ-T3), and intrinsic apoptotic factors; Bcl-2 family in mitochondria and 
caspase 3 (common targets of γ-T3 and statins). 
 
 
 
 
 
 
 
 
 
Fig. A structural formula of tocotrienol 
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Chapter1 
 
Synergistic effect of combined treatment with gamma-tocotrienol 
and statin on human malignant mesothelioma cells 
 
 
Introduction 
 
The product of HMGR, mevalonate (MVL), is the precursor for many important 
intermediates in a pathway commonly known as “mevalonate pathway”. Inhibition 
of HMGR leads to block the formation of many intermediate products such as 
farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), which 
isoprenylate various proteins, including small G-proteins such as the Ras/Rho super 
family proteins [42]. Ras communicates with a number of downstream targets 
involved in cell function. Two targets, the PI3K/Akt pathway and the 
Raf/MEK/MAPK/ERK pathways are involved in apoptosis and cell cycle progression. 
Therefore, the cancer prevention activity reported for statin is believed to be due to 
their inhibition of isoprenylation of G-proteins and subsequent alteration of 
downstream signaling pathways. On the other hand, the mechanisms of action by 
which γ-T3 and statins suppress HMGR activity are different [43]. In most cases, 
the combination of γ-T3 with statin exhibits better anticancer activity than either 
agent alone [26,27,44,45]. For example, combining low dose γ-T3 and statin was 
shown to inhibit the growth of highly malignant mammary epithelial cells [44]. In 
addition, atorvastatin (ATV) and γ-T3 exhibited a strong synergistic effect against 
human colon cancer cells and caused cell cycle arrest and apoptosis [27]. Moreover, 
both γ-T3 and statin also have reported to have HMGR-independent targets. For 
example, statins inhibit the protein degradation machinery, specifically the 
proteasomes. Inhibition of proteasome activity is likely to be related to the effect of 
statins in G1 cell cycle arrest [27]. In general, statins exert their cancer prevention 
effects by regulating several disease-associated cellular events including 
inflammation, immunomodulation, angiogenesis, apoptosis and proliferation [26,27]. 
With regard to γ-T3, it has been well-studied about its endoplasmic reticulum (ER) 
stress inducing effect. Wali et al. suggested that levels of HMGR (it is an 
ER-transmembrane enzyme) decreased following γ-T3 treatment but it might not be 
required for γ-T3 induced apoptosis, whereas ER stress apoptotic signaling was 
associated with γ-T3-induced apoptosis in mammary tumor cells [20]. 
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1.1Cytotoxic effects of a combined treatment with gamma-T3 
and statin 
 
In chapter 1-1, present study is the first to demonstrate the synergetic effect of 
statins (atorvastatin; ATV and simvastatin; SMV) and gamma-tocotrienol (γ-T3) on 
human malignant mesothelioma (MM) at 24 and 48 h.  
 
 
1.1.1 Materials and methods 
 
 [Cell lines and culture conditions] 
The human MM cell lines H2052 (a sarcomatoid), H28 (an epithelioid), H2452 
(an epithelioid), and MSTO-211H (a biphasic; MSTO) cells were obtained from 
the American Type Culture Collection (Rockville, MD, USA) and were cultured 
in RPMI-1640 medium.  
 MSTO and H2052 cells were grown in medium containing 10% fetal bovine 
serum (FBS) (Equitech-Bio, Kerrville, TX, USA), 0.5 units/mL of penicillin, 
and 1 μg/mL of streptomycin.  
 H2452 and H28 cells were grown in the same medium supplemented with 4.5 
g/L of glucose, 1 mM sodium pyruvate, and 10 mM HEPES buffer solution 
(GIBCO, Life Technologies Japan Ltd., Minato-ku, Tokyo, Japan). All cell 
lines were maintained at 37 °C in a fully humidified atmosphere of 5% CO2. 
 
[Reagents] 
All cultures and reagents were purchased from Sigma Chemical Company (St. 
Louis, MO, USA) unless otherwise indicated. γ-T3 was a gift from Dr. Yano T (Toyo 
University). Simvastatin (SMV) was purchased from Cayman Chemical Company 
(Ann Arbor, MI, USA) and atorvastatin (ATV) was purchased from LKT 
Laboratories, Inc. (St. Paul, MN, USA).  
 
1) RPMI1640 (SIGMA) 
2) FBS (EQUITECH-BIO, SIGMA) 
3) Penicillin-Streptomycin (Antibiotics) (GIBCO) 
4) 100mM Sodium Pyrvate (GIBCO) 
5) HEPES Buffer Solution (1M) (GIBCO) 
6) D-Glucose (GIBCO) 
10 
 
7) Dulbecco’s PBS(－) (Nissui Pharmaceutical Co.,Ltd) 
8) 0.25% Trypsin-EDTA solution (SIGMA) 
9) 0.4% Trypan blue solution (SIGMA) 
10) Dimethyl sulfoxide(DMSO) (Wako) 
11) Ethanol(Wako) 
12) T3 content 39.3% of γ-T3 
→γ-T3 is 3mM Was dissolved in FBS and ethanol. 
13) Simvastatin (SMV) (Cayman Chemical)  
14) Atorvastatin (ATV) (LKT Laboratories, Inc) 
→Was dissolved in DMSO so that the 100mM. 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (DOJINDO)
→MTT was dissolved in PBS so as to have a 5 mg / ml, was prepared at the 
time to 0.25 mg / ml by using (1% Antibiotics) serum-free medium. 
 
[Cytotoxicity assay (MTT assay)] 
Cytotoxicity studies were performed in 96-well plates. The cells were cultured at a 
density of 3.0 × 103 cells per well in 100 μL of RPMI-1640 medium for 24 h, then 
started incubation with γ-T3, statin (ATV, SMV), combination of “γ-T3 + ATV” and 
“γ-T3 + SMV”. After the cells were incubated for 24 or 48 h, 100 μL of MTT 
solution (500 μg/mL) was added to each well and incubated for 1 h. Formazan 
crystals were dissolved in DMSO (100 μL/well). The absorbance was measured at 
540 nm with a Multiskan JX microplate reader (Thermo Lab Systems, Cheshire, 
UK). 
 
[Cell cycle analysis] 
Cells were plated at a density of 2.0 × 105 cells in a 60-mm dish and incubated 
for 24 h prior to treatment with γ-T3, statin (ATV, SMV), or a combination of γ-T3 
and statin for 24 h. Thereafter, the cells were collected and fixed in 70% ice-cold 
ethanol at −30 °C. Before the analysis, the cells were treated with 200 μg/mL 
RNase A and 50 μg/mL of propidium iodide for 30 min in the dark at 37 °C. The 
stained cells were analyzed using flow cytometry by using a MoFlo cell sorter (Dako 
Cytomation, Kyoto, Japan). 
 
[Statistical analysis] 
We performed at least three independent experiments, and all data are presented 
as mean ±  standard deviation (SD) or standard error of the mean (SEM). 
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Statistical analysis was performed using the Tukey–Kramer test for the comparison 
of multiple groups. Values with p < 0.05 were considered statistically significant. 
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1.1.2 Results 
 
The cytotoxic effects of γ-T3 and statin either alone or in combination on human 
MM cells were examined. As shown in Fig. 1.1.1, ATV (Fig. 1.1.1a) and SMV (Fig. 
1.1.1b) decreased the cell viability of human MM cells; however, each statin alone 
did not exert significant effects compared to the control. Compared to γ-T3 or statin 
alone, the combination treatment significantly inhibited the growth of human MM 
cells. Additionally, the combination treatment effect occurred in a time-dependent 
manner. To examine the mechanism of the combination effect, MSTO and H2452 
cells, which were especially sensitive to the combination among four cell lines, were 
selected for the experiments that follow.  
 
DNA damage causes cell cycle arrest. Cells with irreversible damage might 
undergo apoptosis, causing an accumulation of cells in sub-G1 phase [46]. As shown 
in Fig. 1.1.2, almost no phase shift was observed in MSTO cells that were treated 
with γ-T3 (20 μM), ATV, or SMV (6.25 μM) alone for 24 h. On the other hand, the 
sub-G1 population appeared to slightly increase in the group treated with a 
combination of γ-T3 and statin. This population was also higher in groups treated 
with ATV or SMV for 48 h than that in untreated control cells. Moreover, there was 
a 3- to 8-fold increase in sub-G1 cells in groups treated for 48 h with a combination 
of γ-T3 and ATV (or SMV) than in untreated control cells. 
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(a) γ-T3+ATV  
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Fig. 1.1.1 Effects of γ-T3 given alone or in combination with statins on human 
MM cells. Cells (MSTO, H2452, H2052, and H28) were seeded in 96-well plates and 
treated for 24 or 48 h with γ-T3 (20 μM) alone or in combination with (a) ATV (6.25 
μM) or (b) SMV (6.25 μM). Cell viability was evaluated using the MTT assay. Data 
are expressed as mean ±  S.D of at least three independent experiments. 
Significant differences between each of the indicated groups were determined using 
the Tukey–Kramer test.  **p < 0.01; ***p < 0.001. 
(b) γ-T3+SMV  
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(a) 
 
Fig. 1.1.2 Effects of combination treatment with γ-T3 and statins on the cell cycle 
distribution in MSTO cells. Cells were treated with γ-T3 (20 μM) alone or in 
combination with ATV (6.25 μM) or SMV (6.25 μM) for (a) 24 h or (b) 48 h. Each 
parameter was determined using fluorescence-activated cell sorting (FACS) 
analysis. Columns represent the mean value of a relative percentage of cells in each 
cell cycle phase over the time course. Data were obtained from three independent 
experiments. 
control γT3 ATV γT3 
+ATV 
γT3 
+SMV 
SMV 
control γT3 ATV γT3 
+ATV 
γT3 
+SMV 
SMV 
(b) 
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1.2 Combination effects of on HMGR levels 
 
In chapter 1-2, demonstrate the synergetic effect of statins (ATV and SMV) and 
γ-T3 on human MM cells. Involvement of Mevalonate upstream pathway HMGR 
mRNA expression. 
 
 
1.2.1 Materials and methods 
 
[Cell lines and culture conditions] 
Refer to 1.2.1 Materials and methods. 
 
[Real-time RT-PCR analysis] 
Total RNA was isolated using an RNeasy® Mini Kit (Qiagen, Valencia, CA, USA), 
and cDNA was synthesized using a PrimeScript RT Reagent Kit (Takara, Shiga, 
Japan). Real-time reverse transcription (RT) PCR was performed using the ABI 
StepOne Real-time PCR System (Applied Biosystems Japan Ltd, Tokyo, Japan) 
using SYBR® Premix ExTaq™ (TaKaRa Bio Inc., Shiga, Japan) according to the 
manufacturer ’ s instructions. The sequences of primers used to amplify 
3-hydroxy-3-methylglutaryl CoA reductase (HMGR), and ribosomal protein L32 
(RPL32) are shown in Table 1. The PCR was performed at 95 ℃ for 10 s followed by 
40 cycles of 95 °C for 5 s and 60 °C for 31 s. All data were normalized to the 
internal standard RPL32. 
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＜Reverse transcription (RT) reaction＞ 
 
Reagents：PrimeScript RT reagent Kit (Perfect Real Time) (TaKaRa) 
Equipment：PCR Thermal Cycler (TaKaRa) 
Composition：                   
                Volume（/tube） 
①5×PrimeScript Buffer (for Real Time)   2 l  
②PrimeScript RT Enzyme Mix I      0.5 l  
③Oligo dT Primer             0.5 l  
④Random 6 mers            0.5 l  
RNA template             0.25 g 
⑤RNase Free dH2O               
 Total                 10 l  
 
＜Real-time PCR＞ 
 
Reagents：SYBR Premix Ex Taq (Perfect Real Time) (TaKaRa) 
Equipment：ABI StepOne Real Time PCR System (Applied Biosystems) 
Composition：            Volume（/well） 
                     HMGR / RPL  
SYBR Premix Ex Taq (2×)               10 l  
Primer Mix（10 M）                   0.4 l 
ROX Reference Dye (50×)               0.4 l 
D.W                                   7.2l 
cDNA template 2 l      
Total     20 l     
 
Table1 
Sequence of oligonucleotide primers used for real-time quantitative RT-PCR. 
Primer             Sequence 
HMGR (F)  5’-TACCATGTCAGGGGTACGTC-3’   Tm=62.3℃ 
 (R)  5’-CAAGCCTAGAGACATAATCATC-3’  Tm=57.0℃  
<Product: 153bp>   
RPL32 (F) 5’-CATCTCCTTCTCGGCATCA-3’   Tm=64.0℃  
(R)  5’-AACCCTGTTGTCAATGCCTC-3’     Tm=63.9℃ 
RPL32 was used as an internal standard. 
Transcription reaction 
37℃ 15 min 
85℃  5 sec 
4℃  ∞ 
Transcription reaction 
95℃ 10 sec 
95℃  5 sec   40 cycle 
60℃ 31 sec 
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1.2.2 Results 
 
The effects of single treatment of γ-T3 (20 μM)/ATV (6.25 μM)/SMV (6.25 μM) or 
combined treatment with γ-T3 and one of the statins on HMGR mRNA levels were 
measured using real-time PCR. As shown in Fig. 1.2.1, ATV or SMV (6.25 μM) alone 
significantly increased HMGR mRNA expression approximately 1.5-fold above the 
control levels, although the effect of SMV in H2452 was not significant. On the other 
hand, combined treatment with γ-T3 and ATV or SMV maintained the HMGR 
expression as control level. 
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Fig. 1.2.1 Effects of γ-T3 and statins on HMG-CoA reductase (HMGR) mRNA 
levels in MSTO and H2452 cells. Cells were treated with γ-T3 (20 μM) given alone 
or in combination with ATV (6.25 μM) or SMV (6.25 μM). The mRNA levels were 
determined using real-time RT-PCR after a 24 h incubation, and each mRNA level 
was normalized to the mRNA level of RPL32. Data are expressed as mean ± SEM 
from three independent experiments. Significant differences between each of the 
indicated groups were determined using the Tukey–Kramer test. ***p < 0.001. 
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1.3 Antiproliferative effect of the mevalonate pathway and 
downstream factors 
 
In chapter 1-3, demonstrate the synergetic effect of statins (ATV and SMV) and 
γ-T3 on human MM cells. Involvement of the mevalonate pathway downstream 
intermediates, including FPP, GGPP and MVL. Then investigation of downstream 
factors Akt and ERK protein expression.  
 
 
1.3.1 Materials and methods 
 
[Cell lines and culture conditions] 
Refer to 1.2.1 Materials and methods. 
 
[Reagents and antibodies] 
P44/42 MAP Kinase (137F5), Phospho-p44/42 MAPK (Thr202/Tyr204), and 
Rabbit monoclonal antibodies were obtained from Cell Signaling Technology Inc. 
(Danvers, MA, USA). Anti-AKT (rabbit) polyclonal and Anti-AKT pS473 (mouse) 
monoclonal antibodies were purchased from Rockland Immunochemicals 
(Gilbertsville, PA, USA). 
 
[Cytotoxicity assay (MTT assay) with intermediates of mevalonate 
pathway] 
Cytotoxicity studies were performed in 96-well plates. The cells were cultured at a 
density of 3.0 × 103 cells per well in 100 μL of RPMI-1640 medium for 24 h, then 
started incubation with γ-T3, statin (ATV, SMV), combination of “γ-T3 + ATV”, and 
“γ-T3 + SMV”. After the cells were incubated for 24 or 48 h, 100 μL of MTT solution 
(500 μg/mL) was added to each well and incubated for 1 h. Formazan crystals were 
dissolved in DMSO (100 μL/well). The absorbance was measured at 540 nm with a 
Multiskan JX microplate reader (Thermo Lab Systems, Cheshire, UK). Mevalonate 
(MVL) pathway is one of the main and common targets for both γ-T3 and statins. 
Therefore, to examine the involvement of this pathway with cytotoxic effect induced 
by γ-T3 and statins, cells were then co-treated with intermediate metabolites of 
MVL pathway (these compounds promote the pathway), such as farnesyl 
pyrophosphate (FPP; 5 μM), geranylgeranyl pyrophosphate (GGPP; 5 μM), or MVL 
(50 μM) in addition to γ-T3 and statins. High concentrations of MVL (100, 200 μM) 
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were also examined to elucidate if the effect is concentration dependent or not. 
 
[Western blotting analysis] 
Human MM cells were cultured at a density of 1.0 × 106 cells in a 60-mm dish for 
24 h. The cells were then harvested and lysed in ice-cold lysis buffer (50 mM 
Tris–HCl [pH 6.5], 10% glycerol, 10% β-mercaptoethanol, 0.5 mM phenylmethane 
sulfonyl fluoride [PMSF] solution, 2% sodium dodecyl sulfate [SDS] [Wako], 1 mM 
sodium orthovanadate, and 1% protease inhibitor cocktail). The cells were 
incubated on ice for 20 min following centrifugation for 10 min at 12,000 rpm and 
4 °C. Samples containing 20 μg of protein were electrophoresed through a 10% 
SDS–polyacrylamide gel and transferred to a polyvinylidene difluoride (PVDF) 
membrane (Atto Corp, Tokyo, Japan). The membranes were blocked with TBS-T 
(13.7 mM NaCl, 2.5 mM Tris, 0.05% Tween20 [Wako]) containing 5% skim milk 
(Yukijirushi, Tokyo, Japan) for 1 h, incubated with primary antibodies for 1 h, and 
incubated with secondary antibody for 1 h. The antibody dilutions were as follows: 
ERK (1:1000), P-ERK and AKT (1:2000), P-AKT (1:3000), and ß-actin (1:2000). All 
antibodies were diluted with TBS-T containing 0.1% skim milk. ß-actin was used as 
the internal standard. Detection was accomplished using Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, Tokyo, Japan) and an LAS-1000plus 
Image Analyzing System (Fujifilm, Tokyo, Japan). 
 
[Statistical analysis] 
  Refer to 1.1.1 statistical analysis. 
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1.3.2 Results 
 
To examine whether cytotoxicity induced by γ-T3 and statin was involved in the 
modulatory effects of the MVL pathway, the cells were cultured with γ-T3, ATV, and 
SMV in the absence (control) or presence of 5 μM FPP, 5 μM GGPP, and 50 μM MVL 
Cell viability was measured using the MTT assay. FPP did not have a significant 
effect on the viability of MSTO or H2452 cells. On the other hand, the addition of 
GGPP and MVL increased cell viability, which was more readily apparent at 48 h 
than at 24 h in MSTO cells (Fig. 1.3.1a). Additionally, the viability of cells treated 
with γ-T3, ATV, and SMV was examined in the absence or presence of 50 μM, 100 
μM, and 200 μM MVL (Fig. 1.3.1b). The results suggest that MVL treatment 
reversed the growth inhibitory effect of the combined treatment (γ-T3 with ATV or 
SMV) in both MSTO and H2452 cells. 
 
Oncogenes promote cell cycle progression (i.e., cell proliferation) via regulation of 
intracellular signaling pathways. Two major pathways that are intimately involved 
in the G1-to-S transition are the RAS-activated RAF-MEK-ERK and PI3-AKT 
pathways. PI3K-AKT is known to impart a strong survival signal that potentially 
raises the cellular threshold for apoptosis. Therefore, AKT is frequently activated in 
MM cells [47]. However, γ-T3 and statin (either alone or in combination) did not 
affect AKT phosphorylation (Fig. 1.3.2a). On the other hand, γ-T3 and statin (alone 
or in combination) significantly inhibited ERK phosphorylation in MSTO cells (***: 
p < 0.001). No effects were noted in H2452 cells. These results suggest that γ-T3 and 
statin inhibit the downstream signaling of the MVL pathway, which partially 
contributes to the inhibition of cell growth (Fig. 1.3.2b). 
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Fig. 1.3.1 Effect of combined treatment with γ-T3 and statins on the MVL 
pathway in MSTO and H2452 cells. (a) Under stimulation with FPP (5 μM), GGPP 
(5 μM), and MVL (50 μM), growth inhibitory effects induced by γ-T3, ATV, and SMV 
were examined in MSTO and H2452 cells. (b) The effect of MVL (50–200 μM) on the 
growth inhibition induced by γ-T3, ATV, and SMV in MSTO and H2452 cells was 
examined. Cell viability was determined using the MTT assay. Data are expressed 
as mean ± S.D from three independent experiments. In each treatment group, 
significant differences from (a) no metabolites or (b) MVL 0 μM were determined 
using the Tukey–Kramer’s test. *p < 0.05; **p < 0.01; ***p < 0.001. 
(b) 
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Fig. 1.3.2 Effects of a combined treatment with γ-T3 and statins on the expression 
levels of growth factors located downstream of the MVL pathway in MSTO and 
H2452 cells. Cells were treated with γ-T3 (20 μM), ATV (6.25 μM), or SMV (6.25 μM) 
given alone or in combination for 24 h. Subsequently, (a) Akt activation and (b) ERK 
activation levels were examined. Protein expression levels were determined using 
western blotting analysis. The bar graph shows the ratio of phosphoprotein density 
to total protein density. Data are expressed as mean ± SEM of four independent 
experiments. ***p < 0.001 vs. control by the Tukey–Kramer test. 
 
(b) ERK activation  
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1.4 Effect on intrinsic apoptosis 
 
In chapter 1-4, demonstrate the synergetic effects of intrinsic apoptosis, 
unchanged expression of Bcl-2 family proteins and activation of caspase 3 on statins 
(ATV and/or SMV) and γ-T3 in human MM cells. 
 
 
1.4.1 Materials and methods 
 
[Cell lines and culture conditions] 
Refer to 1.2.1 Materials and methods. 
 
[Reagents and antibodies] 
Bax (N-20), Purified mouse anti-Bcl-2 and monoclonal anti-ß-actin were obtained 
from Sigma Chemical Company (St. Louis, MO, USA). Donkey anti-rabbit IgG, 
HRP-conjugate and Goat anti-mouse IgG, HRP-conjugate were purchased from 
Beckam Coulter (Tokyo, Japan).  
 
[Cytotoxicity assay (MTT assay)] 
Refer to 1.1.1 Materials and methods. 
 
[Western blotting analysis] 
It is the same as 1.3.1 Materials and methods except for antibodies’ condition.  
The antibody dilutions were as follows: The antibody dilutions were as follows: 
Bax (1:1000), Bcl-2 (1:500), and ß-actin (1:2000). Bax and ß-actin were diluted with 
TBS-T containing 0.1% skim milk. Bcl-2 was diluted with Immuno Enhancer (IE). 
ß-actin was used as the internal standard. 
 
[Caspase 3 activity assay] 
1.0 × 106 cells were cultured in 60-mm dishes for 24 h. Subsequently, the cells 
were harvested and centrifuged, and the cell pellets were washed with 2 mL of PBS. 
Then the caspase 3-activity assay was performed according to the manufacturer’s 
protocol (Biovision, Mountain View, CA, USA). In brief, 100 μL of cold lysis buffer 
was added to the cell pellets. Subsequently, the cell pellets were incubated for 10 
min on ice, and the lysate was centrifuged at 10,000 rpm for 1 min at 4 °C. The 
supernatant was transferred into a micro-centrifuge tube and mixed with the DC 
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Protein Assay Reagent (Bio-Rad, Tokyo, Japan). Supernatants (50 μL) were 
dispensed into a 96-well plate (100 μg of protein/well). We then added 10 μL of DTT 
to 1 mL of 2 × reaction buffer and dispensed 50 μL of this mixture into each well in 
addition to 5 μL of 4 mM DEVD-pNA substrate. The plate was then incubated for  
2 h at 37 °C. To detect caspase 3 activity, the absorbance was measured at 405 nm 
with a microplate reader. 
 
[Statistical analysis] 
Refer to o 1.1.1 statistical analysis. 
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1.4.2 Results 
 
The expression of Bax, a pro-apoptotic protein, did not change after γ-T3 or statin 
treatment. Similarly, the expression of Bcl-2, another cell death-associated protein, 
did not change (Fig. 1.4.1). On the other hand, a combination of γ-T3 and ATV or 
SMV caused a strong induction of caspase 3 activity in both in MSTO and H2452 
cells (Fig. 1.4.2). Treatment with ATV alone also strongly activated caspase 3 in 
MSTO cells (Fig. 1.4.2a); therefore, the effect might be mainly due to statins. The 
caspase 3 inhibitor Z-DEVD-FMK significantly inhibited the reduction in MSTO 
cell viability in response to ATV treatment, although the cell viability was not 
reversed in H2452 cells even after treatment with Z-DEVD-FMK (Fig. 1.4.2b).  
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Fig. 1.4.1 Effects of a combined treatment with γ-T3 and statins on the expression 
levels of Bcl-2 and Bax proteins in MSTO and H2452 cells. Cells were treated with 
γ-T3 (20 μM), ATV (6.25 μM), or SMV (6.25 μM) given alone or in combination for 24 
h. Subsequently, Bax and Bcl-2 protein expression levels were examined. Each 
protein expression level was determined and quantified using western blotting. 
ß-actin was used as an internal standard. The lower columns indicate the Bax/Bcl-2 
ratio, which illustrates the apoptotic balance. Data are expressed as mean ± SEM 
of four independent experiments.  
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Fig. 1.4.2 Effects of a combined treatment with γ-T3 and statins on caspase 3 
activity in MSTO and H2452 cells. Cells were treated with γ-T3 (20 μM), ATV 
(6.25 μM), or SMV (6.25 μM) given alone or in combination for 24 h. Subsequently, 
(a) the activity of casepase-3 in MSTO and H2452 cells was examined. Caspase 3 
activity was detected as absorbance at 405 nm. (b) The effect of a caspase 3 
inhibitor (Z-DEVD-FMK) on apoptosis induced by ATV in MSTO and H2452 cells 
was analyzed. The cells were treated with ATV (6.25 μM) in the absence or 
presence of Z-DEVD-FMK (2 μM). Cell viability was measured using the MTT 
assay. ***p < 0.001 vs. control; ##p < 0.05 vs. ATV by the Tukey–Kramer test. 
Data are expressed as mean ± S.D of three independent experiments. Cell 
viability was measured using the MTT assay. ***p < 0.001 vs. control; ##p < 0.05 
vs. ATV by the Tukey–Kramer test. Data are expressed as mean ± S.D of three 
independent experiments. 
(b) 
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1.5 Discussion 
 
Malignant mesothelioma cells exhibit resistance to single-agent and combination 
chemotherapy strategies, therefore successful chemotherapy is a key point for the 
treatment of these patients [48]. Now pemetrexed and cisplatin combination 
chemotherapy is the first-line treatment in inoperable disease with a median 
survival of 9 – 12.4 months [49]. Despite notable improvement using this 
combination therapy, disease recurrence and progression remain a problem. On the 
other hand, one previous study addressing the efficacy of γ-T3 combination 
treatment with cisplatin-induced cytotoxicity in human mesothelioma H28 cells in 
culture has been reported [50]. Additionally, several in vitro [27] and in vivo [51] 
studies support the anticancer effect of γ-T3 alone or in combination with statin.  
Cytostatic effects were observed when 20 μM of γ-T3 was combined with 6.5 μM 
of ATV or 6.5 μM of SMV (Fig. 1.1.1). Previous study has shown that combining 
low-dose γ-T3 and statin induced cell cycle arrest at G1 in mammary tumor, leading 
to a large reduction in cyclin D1 and a marked increase in p27 expression; however, 
γ-T3 or statin alone had little or no effect on the distribution of cells in different cell 
cycle phases compared with the combining group [52]. On the other hand, γ-T3 
inhibited human gastric adenocarcinoma (SGC-7901) cell growth at the G0/G1 
phase [53]. Our results indicate that the sub-G1 population is increased by 
combination treatment with γ-T3 and statins, and such an increase is an indicator 
of apoptosis. No phase shift was observed in MSTO cells treated with γ-T3 (20 μM), 
ATV (6.25 μM), or SMV (6.25 μM) alone for 24 and 48 h (Fig. 1.1.2). These results 
suggest that the effects of γ-T3 or statin on cell cycle distribution may be dependent 
on cell types. Further studies are needed to confirm which phase is a major target. 
It has been reported that the synergistic effects of γ-T3 and statin appear to result 
from the cooperative action of γ-T3, which down-regulates HMGR mRNA expression, 
and statins, which directly inhibit HMGR activity [43]. Several studies have been 
performed to determine if the antiproliferative effects of combined statin and γ-T3 
treatment result solely from the inhibition of HMGR or if additional 
HMGR-independent mechanisms are involved [26,43]. In the present study, a 
decreasing trend of HMGR mRNA expression was observed in both MSTO and 
H2452 cells treated with γ-T3; however, this decrease was not significant compared 
to control in both cell lines. On the other hand, statins alone increased the mRNA 
expression, which was also shown in previous reports [54,55]. This statin-induced 
increase was reversed by co-treatment with γ-T3 (Fig. 1.2.1). Previous reports 
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support our results: tocotrienols have been shown to reduce HMGR activity by 
triggering (1) the retention of sterol regulatory element binding proteins (SREBPs), 
which are membrane-bound transcription factors that activate all of the genes 
required to produce cholesterol, in the ER and (2) the degradation of HMGR by 
stimulating ubiquitination or reduction in mRNA level [45,56]. Moreover, the ability 
of sub-effective doses of γ-T3 to synergistically enhance the growth inhibitory effects 
of statins can be explained, at least in part, on the basis of the finding that statin 
inhibition of HMGR activity is associated with a compensatory feedback mechanism 
that results in the up-regulation of HMGR expression [44]. Therefore, synergistic 
attenuation of HMGR activity via the application of the 2 compounds might 
contribute to strong growth inhibition. 
Next, to investigate whether the anticancer activity of combination (γ-T3 + statin) 
therapy is mediated via inhibition of the MVL pathway, the effects of exogenous 
intermediates of this pathway on cell growth were examined. The inhibition of 
HMGR by statins leads to reduced production of cholesterol and isoprenoids as well 
as downstream intermediates, including MVL (the first product of this pathway), 
FPP, and GGPP [57]. Human farnesyl pyrophosphate synthase (hFPPS) is 
responsible for the catalytic elongation of dimethylallyl pyrophosphate (DMAPP) to 
FPP via the successive condensation of 2 isopentenyl pyrophosphate (IPP) units, 
and it controls the intracellular levels of all downstream isoprenoids, including 
GGPP [58]. Moreover, the angiostatic effects of statins at high therapeutic 
concentrations are lipid-independent and are reversible by supplementation with 
MVL and GGPP [59]. Both FPP and GGPP are important lipid attachments 
required for the post-translational modification of a variety of small GTPase 
proteins such as Ras and Rho GTPases. Thus, inhibitors of the MVL pathway might 
have the opportunity to inhibit the invasion of cancer cells, as was reported for 
HMGR inhibitors [60]. In the present study, the inhibition of cell growth by γ-T3 
and statin was reversed after the addition of MVL or GGPP in a dose-dependent 
manner (Fig. 1.3.1). Therefore, the synergistic antiproliferative effects of combined 
γ-T3 and statin treatment may result directly from an inhibition of HMGR activity 
and subsequent suppression of MVL synthesis. 
The Raf/MEK/MAPK/ERK pathway and the PI3K/AKT pathway are important 
downstream targets of activated Ras. ERK and AKT are vital growth factors 
involved in cell cycle promotion and apoptosis regulation. We investigated whether 
there was any change in protein expression among the treated cells; however, 
neither the single nor the combination treatment altered AKT expression (Fig. 
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1.3.2). On the other hand, γ-T3 and statin (alone or in combination) significantly 
inhibited ERK phosphorylation in MSTO cells (Fig. 1.3.2). Therefore, the growth 
inhibition observed in the present study might mainly occur via ERK signaling. It 
was previously shown that γ-T3 inhibits cell growth in sympathoadrenal (SA) + 
mammary cells specifically by suppressing EGF-dependent Stat and AKT mitogenic 
signaling [45]. This disparity in response to γ-T3 might be derived from the 
different characteristics of each cancer type. 
Indeed, AKT is often activated in both primary tumor and MM cell lines [47]. Our 
results also showed positive AKT phosphorylation in all the cells, which was not 
affected by any treatment. MMs with a positive AKT phosphorylation status have 
also been shown to be phosphorylated (activated) mammalian targets of rapamycin 
(mTOR), a molecule that functions downstream of the AKT pathway [47]. Moreover, 
a PTEN homozygous deletion, which was also responsible for AKT activation, was 
detected in a small subset of MM cell lines [61]. Based on these observations, one of 
the small molecule inhibitors of receptor tyrosine kinases (RTKs), imatinib 
mesylate was used in clinical trial for MM patients; however, a clear effectiveness 
was not observed [62]. This lower-than-expected level of responsiveness was 
thought to be due to the intrinsic resistance of MM cells against RTK inhibitor [47]. 
As a result of this acquired secondary resistance, the effectiveness of inhibitors 
targeted against constitutive activation of a specific RTK is thought to be abrogated 
via a new mutation in the RTK gene or the activation of another RTK. Taken 
together, these results indicate that mono-target therapy will be ineffective in the 
near future for aggressive cancer types such as MM. 
Finally, the effects on the intrinsic apoptotic pathway were investigated. Statins 
initiate apoptosis by suppressing Bcl-2, increasing Bax expression, and activating 
caspase 3 [35]. The propensity of a cell to undergo apoptosis is finely balanced by 
anti-apoptotic and pro-apoptotic factors. The Bcl-2 family has been shown to play an 
important regulatory role in apoptosis either as an activator (i.e., Bax and Bak) or 
as an inhibitor (i.e., Bcl-2 and Bcl-xL). The ratio of Bcl-2 to Bax proteins is 
recognized as a key factor in the regulation of the apoptotic process or cell death [63]. 
Additionally, because the Bcl-2 family proteins are involved in most of the apoptosis 
pathways, they are attractive targets for cancer therapy [64]. Our studies have 
shown that Bax and Bcl-2 were expressed in both MSTO and H2452 cells, but they 
were not affected by γ-T3 and statin. These results are consistent with a previous 
report indicating that γ-T3 induced a mitochondrial disruption pathway without 
affecting Bax/Bcl-2 expression in human breast cancer MDA-MB-231 cells [65]. 
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MM cell lines and tumors were shown to express the Bcl-2 family members Bcl-xL 
and Mcl-1 [66]. The Bcl-2 family is a group of more than 20 protein-coding genes. 
Among these, the Bcl-xL protein is at least as effective as Bcl-2 for preventing 
apoptosis in a variety of human tumors, including MM, when challenged with 
pro-apoptotic stimuli [67]. On the other hand, we found that caspase 3 was 
activated in human MM cell lines by the γ-T3 and statin combination treatment 
(Fig. 1.4.1). Cao et al. showed that Bcl-2/Bcl-xL inhibitors, such as 2-methoxy 
antimycin A3, increased caspase 3 activation without altering the protein 
expression of members of the Bcl-2 family [68]. Therefore, the expression of Bcl-2 
family members should be further examined, and functional assays should be 
performed. 
On the other hand, extent of caspase 3 reactivity induced by statins, especially 
ATV, was the most different point between MSTO and H2452 cells (Fig. 1.4.1). In 
this study, H2452 cells seems to response mildly to stains compared with MSTO 
cells, for example, regarding to ERK activation (Fig. 1.3.2b), casepase 3 activation 
(Fig. 1.4.1). The cause of such difference between cells did not clear out in this study, 
however, caspase 3 original levels might be involved with the different responses. 
Soini et al. showed that there was a tendency for better prognosis of mesotheliomas 
from patients with moderate or intense caspase 3 immunoreativity as compared to 
cases with negative or low caspase 3 [66]. They also indicated that another famous 
apoptotic inducing factor, Fas ligand was not detected in the most drug resistant 
mesothelioma cell line although Fas/Fas ligand has been suggested to participate in 
the apoptosis in mesothelioma cells [69]. Additionally it is suggested that cell origin 
difference might be involved to each responses in MSTO and H2452; MSTO is 
derived from metastatic site (lung) of mesothelioma patients while H2452 is from 
primary tumor though both cell lines are biphasic type. To explore the factor which 
determines drug sensitivity, levels of caspase 3 and other apoptotic markers should 
be examined and be compared between cell lines. 
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1.6 Summary 
 
 
 Combination with γ-T3 and statin induced apoptosis. 
 
 γ-T3 was down-regulated HMGR mRNA expression. 
 
 Growth inhibiting effect by γ-T3 and statin was reversed with MVL or GGPP 
in a dose-dependent. 
 
 γ-T3 and statin alone or combination inhibited ERK phosphorylation. 
 
 Extent of caspase 3 activation was induced by statin, and combination with 
γ-T3 further made further stronger activation. 
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Chapter2 
 
Involvement of endoplasmic reticulum stress with the 
combination effect of gamma-tocotrienol and statin 
 
 
Introduction 
 
The endoplasmic reticulum (ER) stress is defined as accumulation of unfolded or 
misfolded proteins in the ER, which induces monitored and maintained via a 
coordinated adaptive program, the unfolded protein response (UPR) [70]. The 
biochemistry of the ER stress and UPR pathways has been the subject of many 
recent reviews [71]. The investigation of ER-nuclear signaling transduction has 
three signaling pathways [72]: (1) the presence of misfolded or unfolded protein in 
the organelle (unfolded protein response, UPR). (2) The overloading of the ER with 
correctly folded proteins (ER-overload proteins, EOR). (3) The starvation of 
cholesterol (sterol regulatory element binding protein, SREBP).  
There are three branches of UPR that are detected by distinct ER stress 
transducers located on the ER membrane [73]: (1) PER-like endoplasmic reticulum 
kinase (PERK), (2) inositol-requiring enzyme (IRE1), and (3) activating 
transcription factor 6 (ATF6). Moreover, ER stress activates a large number of genes 
involved in the control of cell fate, including antiapoptotic and proapoptotic 
molecules like C/EB homologous protein (CHOP), c-Jun N-terminal kinases (JNK) 
or members of the BCL-2 proteins family [74]. 
PERK is a type 1 transmembrane protein. This activates and phosphorylates 
phosphorylated α subunit of eukaryotic initiation factor 2 (eIF2α) causing a 
translation arrest [75]. IRE1α is an ER transmembrane sensor that activates the 
UPR to maintain the ER and cellular function. Further understanding of IRE1α 
substrate preferences will reveal how IRE1α coordinates cellular homeostasis to 
determine cell fate under ER stress [76]. During ER stress, Ask1 is recruited to 
oligomerized IRE1α complexes containing TRAF2, activating Ask1 kinase and 
causing downstream activation of JNK and P38 MAPK [38]. Release of GRP78 from 
N-terminus of ATF6 triggers different mechanism of protein activation, compared 
with PERK and IRE1α [38].  
In chapter 2, present study is the first to demonstrate the synergetic effect of 
statins and γ-T3 on ER stress in human MM cells. ER stress was evaluated by 
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expression of typical ER stress markers such as CHOP, GRP78, caspase 4 
apoptosis-related cysteine protease (caspase 4) and JNK signaling. Finally 
involvement of caspase family was examined as well. 
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2.1 Materials and methods 
 
 
[Cell lines and culture conditions] 
The human MM cell lines H2452 (an epithelial), and MSTO-211H (a biphasic; 
MSTO) cells were obtained from the American Type Culture Collection 
(Rockville, MD, USA) and were cultured in RPMI-1640 medium.  
 MSTO cells were grown in medium containing 10% fetal bovine serum (FBS) 
(Equitech-Bio, Kerrville, TX, USA), 0.5 units/mL of penicillin, and 1 μg/mL of 
streptomycin.  
 H2452 cells were grown in the same medium supplemented with 4.5 g/L of 
glucose, 1 mM sodium pyruvate, and 10 mM HEPES buffer solution (GIBCO, 
Life Technologies Japan Ltd., Minato-ku, Tokyo, Japan). All cell lines were 
maintained at 37 °C in a fully humidified atmosphere of 5% CO2. 
 
[Reagents] 
All cultures and reagents were purchased from Sigma Chemical Company (St. 
Louis, MO, USA) unless otherwise indicated. γ-T3 was a gift from Dr. Yano T (Toyo 
University). Simvastatin (SMV) was purchased from Cayman Chemical Company 
(Ann Arbor, MI, USA) and atorvastatin (ATV) was purchased from LKT 
Laboratories, Inc. (St. Paul, MN, USA).  
 
[Cytotoxicity assay (MTT assay)] 
Refer to Chapter 1, 1.1.1 Materials and methods. 
Use the following agents to examine ER stress induced apoptosis: 
 Tunicamycin (0.125 μg/ML); ER stress inducer 
 Salubrinal (12.5 μM); Protector from ER stress-induced apoptosis 
 JNK inhibitor (SP600125; 2 μM) 
 Caspase inhibitors (2 μM) [caspase 8 inhibitor (Z-IETD-FMK), caspase 9 
inhibitor (Z-LEHD-FMK), and pan caspase inhibitor (Z-VAD-FMK)] and 
caspase 4 inhibitor (Z-LEVD-FMK; 10 μM) 
 
[Real-time RT-PCR analysis for ER stress markers] 
Refer to Chapter 1, 1.2.1 Materials and methods.  
The sequences of primers used to amplify CHOP, Caspase 4, GRP78, and RPL32 
(internal standard) are shown in Table 2. All data were normalized to the internal 
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standard RPL32. 
 
Table 2 
Sequence of oligonucleotide primers used for real-time quantitative RT-PCR. 
Primer              Sequence 
RPL32 (F) 5’-CATCTCCTTCTCGGCATCA-3’   Tm=64.0℃       
(R)  5’-AACCCTGTTGTCAATGCCTC-3’   Tm=63.9℃ 
<Product: 247bp> 
GRP78 (F)5’-GCTCGACTCGAATTCCAAAG-3’   Tm=63.7℃      
(R)  5’-TTTGTCAGGGGTCTTTCACC-3’   Tm=63.8℃ 
<Product: 331bp> 
CHOP (F)  5’-GAGTCATTGCCTTTCTCCTTCG-3’   Tm=66.0℃       
(R)  5’-TTTGATTCTTCCTCTTCATTTCCA-3’  Tm=64.5℃ 
<Product: 140bp> 
Caspase 4  (F)  5’-CTGAAGGACAAACCCAAGGTCA-3’   Tm=67.2℃ 
(R)  5’-CACTTCCAAGGATGCTGGAGAG-3’   Tm=67.1℃ 
<Product: 96bp> 
RPL32 was used as an internal standard. 
 
[Western blotting analysis] 
Refer to Chapter 1, 1-3-1 Materials and methods.  
The antibody dilutions were shown as follows: JNK (1:1000), pJNK, and ß-actin 
(1:2000). All antibodies were diluted with TBS-T containing 0.1% skim milk. ß-actin 
was used as the internal standard. Detection was accomplished using Immobilon 
Western Chemiluminescent HRP Substrate (Millipore, Tokyo, Japan) and an 
LAS-1000plus Image Analyzing System (Fujifilm, Tokyo, Japan). 
 
[Statistical analysis] 
Refer to Chapter 1, 1.1.1 statistical analysis. 
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2.2 Results 
 
GRP78, CHOP, and caspase 4 are key molecules involved in the ER 
stress-associated apoptosis pathway. Their mRNA expression levels were quantified 
using real-time RT-PCR after 24 h of treatment with γ-T3 and statins given alone or 
in combination. As shown in Fig. 2.2.1a and Fig. 2.2.1b, the expression levels of 
GRP78 and CHOP in MSTO cells significantly increased from baseline in the 
presence of γ-T3. ATV or SMV alone did not affect them at all. In H2452 cells, γ-T3 
also increased GRP78 and CHOP expressions though it seemed milder compared 
with those in MSTO cells (Fig. 2.2.1a and 2.2.1b). Although no differences were 
observed in caspase 4 expression levels in MSTO cells, treatment with γ-T3 alone 
caused a significant increase in the levels in H2452 cells (Fig. 2.2.1c). The response 
to γ-T3 seems also relatively weak in H2452 regarding to ER stress markers, CHOP 
(Fig. 2.2.1a) and GRP78 (Fig. 2.2.1b), although caspase 4 increase by γ-T3 was only 
observed in H2452 cells. Additionally we examined if caspase 4 activation involves 
the combination effect or not with caspase 4 inhibitor (Fig.2.2.2) but cell viability 
after γ-T3 and statin treatment were unchanged both in presence or absence the 
inhibitor. 
 
Tunicamycin (TM) is an ER glycosylation inhibitor that impairs the synthesis of 
proteins in the ER which induces apoptosis. And Salubrinal (Sal) is a selective 
inhibitor of eIF2α dephosphorylation that was recently developed as a protective 
agent against ER stress-mediated apoptosis [77]. Sal alone did not affect cell 
viability so much whereas TM alone decreased the viability to almost 30% compared 
with control (no treatment). In case of the combination with TM and Sal, cell 
viability had been kept around 50%, which was significantly higher than in case of 
TM alone (Fig.2.2.3a). On the other hand, γ-T3 seemed to exhibit similar effect like 
TM; γT3 induced-growth inhibition was recovered with Sal although there was no 
significant difference between γT3 alone and γT3 was combination Sal (Fig.2.2.3b). 
It was considered that the growth inhibitory effect of γ-T3 might be partly occurred 
via ER stress. 
 
Next, as shown in Fig.2.2.4 γ-T3 and statin treated samples were probed by 
western blot analysis for JNK and p-JNK. γ-T3 and ATV alone did not significantly 
alter either JNK or p-JNK levels. On the other hand, p-JNK/JNK ratio was 
significantly increased by γ-T3 and ATV combination comparing with control (p≺
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0.05) in human MM cells. 
 
Then we examined whether such as JNK activation could contribute to the 
growth inhibitory effect or not, using JNK kinase inhibitor, SP600125 with γ-T3 and 
statins. Contrary to our expectation, our results showed that SP600125 did not 
significantly alter the cell viability in cells which were treated with γ-T3, ATV alone 
or combination in neither MSTO nor H2452 cells (Fig.2.2.5). 
 
To determine which caspase are required for the induction of apoptosis by γ-T3, 
ATV alone or combination, cells were treated with caspase 8 inhibitor 
(Z-IETD-FMK), caspase 9 inhibitor (Z-LEHD-FMK) or pan caspase inhibitor 
(Z-VAD-FMK) at a concentration of 2 μM. Any of caspase inhibitors did not block 
cell growth inhibition induced by γ-T3 and statins in MSTO and H2452 cells 
(Fig.2.2.6). 
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Fig. 2.2.1 Effects of combined treatment with γ-T3 and statins on the relative 
mRNA levels of ER stress-associated factors in MSTO and H2452 cells. Cells were 
treated with γ-T3 (20 μM), ATV (6.25 μM), or SMV (6.25 μM) given alone or in 
combination for 24 h. Subsequently, (a) CHOP, (b) GRP78, and (c) caspase 4 mRNA 
expression levels were analyzed. Each mRNA expression level was determined 
using real-time RT-PCR and quantified. The expression levels of each gene were 
normalized to the expression level of RPL32. Data are expressed as mean ± SEM 
of at least three independent experiments.  ***p < 0.001; **p < 0.01 vs. control by 
the Tukey–Kramer test. 
MSTO  
 
H2452  
 
(a) CHOP 
(b) GRP78 
(c) Caspase 4 
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Fig.2.2.2 Effects of caspase 4 inhibitor (Z-LEVD-FMK; 10 μM) treatment with 
γ-T3 (20 μM) and ATV (6.25 μM) alone or combination in MSTO and H2452 cells for 
24 h. Cell viabilities were determined by MTT assay. Data are expressed as mean 
±S.D of at least three independent experiments.  
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Fig.2.2.3 The effects of Salubrinal (Sal) (12.5 μM), Tunicamycin (TM) (0.125 μg/ml) 
and γ-T3 (50 μM) given alone and in combination of each other in MSTO cells for 24 
h. (a) TM induced ER stress (b) γ-T3 induced ER stress. Cell viabilities were 
determined by MTT assay. Data are expressed as mean ±S.E. of at least three 
independent experiments.  ***: p<0.001, **: p<0.01 vs. control by Tukey-kramer’s 
test.  
 
 
(a) 
 
TM induced ER stress 
(b) 
 
γ-T3 induced ER stress  
 
47 
 
 
Fig.2.2.4 Effects of combined treatment with γ-T3 (20 μM), and statins (6.25 μM) 
on the relative expressions of JNK and phosphorylated-JNK (p-JNK) protein in 
MSTO and H2452 cells. p-JNK/JNK ratio was normalized to control in MSTO and 
H2452 cells. Each protein level was determined by western blotting. Data are 
expressed as mean ± S.D of at least three independent experiments.  *:p<0.05 vs. 
control by Tukey-Kramer’s test.  
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Fig.2.2.5 Effects of JNK inhibitor (SP600125; 2 μM) treatment with γ-T3 and ATV 
alone or combination in MSTO and H2452 cells for 24 h. Cell viabilities were 
determined by MTT assay. Data are expressed as mean ±S.D of at least three 
independent experiments. ***: p<0.001 vs. control by Tukey-kramer’s test.  
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Fig.2.2.6 Contribution of caspase family to cell growth inhibition of γ-T3 and ATV 
in MSTO and H2452 cells. Cells were seeded in 96-well plates and treated for 48 h 
with γ-T3 (20 μM), ATV (6.25 μM) alone or in combination with caspase 8 inhibitor 
(Z-IETD-FMK), caspase 9 inhibitor (Z-LEHD-FMK) and pan caspase (Z-VAD-FMK) 
(2 μM). Cell viability was evaluated using the MTT assay. Data are expressed as 
mean ± S.D of at least three independent experiments. ***: p<0.001 vs. control, ###: 
p<0.001 vs. γ-T3 or ATV Tukey-Kramer’s test. 
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2.3 Discussion 
 
In this chapter, we examined the involvement of ER stress with the synergistic 
effect of γ-T3 and statins. ER stress is another expected target of γ-T3. Until now, 
several apoptotic pathways have been identified in cells that are responsive to 
cytotoxic insult, including apoptosis mediated by the activation of death receptors 
(extrinsic), mitochondria-dependent signaling (intrinsic), and ER-induced apoptotic 
cell death. In many instances, deregulation of ER homeostasis has been correlated 
with pathologic states and particularly with cancer [78]. ER stress can lead to 
adaptive responses or apoptosis, both of which follow activation of the UPR [79]. 
The UPR regulator GRP78, an ER chaperone, induces ER stress and is widely 
up-regulated in cancer [51]. Similarly, the activation of CHOP and caspase 4 is a key 
step in ER stress-induced apoptosis [80]. In fact, γ-T3 induced apoptosis may be 
associated with induction of early response genes and the transcriptional response 
to ER stress in breast cancer cells [81]. In the present study, the observed 
up-regulation of GRP78 and CHOP led us to further investigate the involvement of 
ER stress in γ-T3-induced apoptosis. We found that the expression levels of GRP78 
and CHOP were unchanged by treatment with ATV or SMV alone (Fig. 2.2.1a and 
Fig. 2.2.1b). It indicates that statins in the present study did not affect ER stress, 
and also that statins did not inhibit γ-T3 -induced ER stress which might lead the 
following apoptosis. Therefore, this supports the idea that γ-T3 enhances 
statin-induced apoptosis. Although caspase 4 is also a known critical mediator of 
programmed cell death [82], we found that the caspase 4 level was altered only by 
treatment with γ-T3 alone in H2452 cells (Fig. 2.2.1c). Result of MTT assay using 
caspase 4 inhibitor also suggested it was not significant factor for growth inhibitory 
effect of γ-T3 and statins in the present study (Fig. 2.2.2). 
The TM inhibits protein glycosylation in the ER, there by inducing ER stress. 
Apoptosis is induced by severe and prolonged ER stress [77]. Salubrinal protected 
MSTO cells from cytotoxicity induced by TM, as demonstrated by increased cell 
viability. A recent study has shown that phosphorylation of eIF2α protected cells 
from ER stress [83]. And TM is the most commonly used pharmacological agent to 
experimentally induce ER stress [84]. As shown in Fig.2.2.3b, γ-T3 induced 
cytotoxicity was slightly recovered by salubrinal which suggests the ER stress has a 
role in γ-T3-induced growth inhibition; however, it was not significant change. 
Another assay which detects apoptosis from the different aspect, such as 
flowcytometry and TUNEL assay, will support to understand the role of ER stress 
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in the present case. 
The, JNK belong to the mitogen-activated protein kinase (MAPK) family. JNK 
studies provided a mechanistic link between stress and growth factor [85]. Moreover, 
JNK is important role in cell stress reactions and being activated by many 
extracellular stress signals, JNK is also called stress activated protein kinase 
(SAPK), and is involved in stress reaction and cell death [86]. Our results indicated 
that p-JNK/JNK ratio was significantly increased by γ-T3 combination with ATV, 
but not affected by γ-T3 or ATV single treatment (Fig.2.2.4). A recent report 
suggested JNK as a mediator of simvastatin- induced growth inhibition and cell 
death in breast cancer cells [87]. Another report suggested that γ-T3 induces 
apoptosis through activation of JNK signaling via ER stress in breast cancer cells 
[88]. Moreover, the regulation of JNK transduction pathway also has been 
mentioned in tumorigenesis and metastatic potential of gastric cancer [89]. JNK is 
known to be activated by ER stress through the IRE1α pathway, but the interplay 
with mitochondria and the mechanism for sustained JNK activation in ER stress is 
not known [90]. In response to ER stress, the kinase domain of IRE1 binds to the 
TRAF2 adaptor molecule and activates the apoptosis signaling regulation kinase 
(ASK1), which in turn the causes the phosphorylation and activation of JNK. 
However, JNK signaling elicits many cellular responses besides cell death and can 
even promote cell survival in specific circumstances [91].  
SP600125 is a specific, small molecule inhibition of JNK that prevents the 
phosphorylation of c-Jun and blocks the expression of proinflammatory cytokines 
and subsequent apoptosis cell death [92]. Hence, SP600125 treatment significantly 
induced apoptosis consistent with the increasing levels of phosphorylated 
anti-apoptotic proteins like Bcl-2 and Bcl-xL (un-activated form) in U937 leukemia 
cells [93]. In recent report shown that downstream of JNK activates caspases via 
the translation of Bax to mitochondria from the cytosol. The translocated Bax 
induces an increase of mitochondrial membrane permeabilization and cytochrome c 
release [94]. In the recent report provided further details for the action mechanism 
of SP600125 on the ER and mitochondrial functions [95]. Considering these reports, 
the action of SP600125 used in our study should be revised carefully. There is still a 
possibility that results would be changing by the concentrations or timing of 
SP600125 when it was treated with γ-T3 (Fig.2.2.5). Further studies are needed 
that concentrate on more efficient upstream signals leading to the JNK activation 
as well and this notion remains to be tested. 
Caspase are the final effectors of both extrinsic and intrinsic apoptosis, 
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therefore it is expected that interfering with their function impairs these pathway 
leading to a survival advantage for cancer cells and indeed caspase alterations are 
not rare in a variety of tumors [96]. It has been demonstrated those two pathways 
through which the caspase family proteases can be activated: one is the death 
signal-induced, death receptor-mediated pathway; the other is the stress-induced, 
mitochondrion-mediated pathway [97]. Typically, the death receptor-initiated 
pathway involved activation of initiator caspase 8, which in turn activates caspase 3 
[97]. In addition, caspase 3 and caspase 9 as well as caspase generated truncated 
Bid that triggers cytochome c release [98]. There is a report that when the caspase 
12 activity was inhibited by Z-ATAD-FMK, the mitochondria dependent activation 
of caspase 9 and caspase 3 was not provoked to a sufficient level required for 
subsequent activation of caspase 8 in Jurkat T cells [99]. On the other hand, in all 
MM cell lines, Z-VAD-FMK 10 µM resulted no significant effect on 
sorafenib-mediated cell killing whereas the caspase inhibitor did potently inhibit 
the cytotoxicity of TRAIL in those cell lines sensitive to TRAIL [100]. Therefore, 
they didn’t significantly affect the synergistic cell growth inhibition of γ-T3 and 
statin that needed to explore the molecular mechanisms of ER stress.  
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2.4 Summary 
 
 
 γ-T3 increased ER stress markers; GRP78 and CHOP but not caspase 4. 
 
 γ-T3 induced growth inhibition was slightly blocked by salubrinal, a protector 
of ER stress related apoptosis in MSTO cells. 
 
 γ-T3 and statin (ATV) combination up-regulated JNK activation but it had 
almost no effect on their synergistic growth inhibitory effect. 
 
 Caspase 8 and caspase 9 inhibitors did not significantly change cell 
cytotoxicity induced by γ-T3 and statin (ATV, SMV). 
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Conclusion 
 
 
In this study, we analyzed that treatment effect of γ-T3 and statin exhibited a 
synergistic effect against human malignant mesothelioma cells in vitro. 
 
In Chapter1, synergistic effect of combined treatment with gamma-tocotrienol and 
statin on human malignant mesothelioma cells was revealed. 
γ-T3 and statin exhibited a synergistic effect against human MM cells by 
complimentary and synergetic mechanism; inhibition of the MVL pathway 
including HMGR and the following MAPK signaling (induced by both γ-T3 and 
statin), and caspase 3 activation (induced by statin). Whether caspase 3 activation 
was derived from MVL pathway or not had not been confirmed yet. In this study, 
stains were used at 6.25 μM when combined with γ-T3. It still seems a little bit high 
concentration in consideration of previous clinical tolerance of statin [37], however, 
there is a possibility that lower than 6.25 μM concentration of statins combined 
with high concentration of γ-T3 (more than 20 μM) could work effectively since γ-T3 
is assumed to be safe. Moreover, our combination use of γ-T3 and statin has shown 
not only cytostatic effect but also cytotoxicity, as shown sub-G1 increase and caspase 
3 activation.  
 
In Chapter2, it was revealed that endoplasmic reticulum stress seemed to be 
involved with the combination effect of γ-T3 and statin.  
Our work found that the expression levels of GRP78 and CHOP were 
unchanged by treatment with ATV or SMV alone (Fig. 2.2.1a and b). It indicates 
that statins in the present study did not affect ER stress, and also that statins did 
not inhibit γ-T3 induced ER stress which might lead the following apoptosis. Then 
we used ER stress factors such as JNK and caspase family members, caspase 8 and 
caspase 9 which are reported to be related with ER stress, although they didn’t 
significantly affect the synergistic cell growth inhibition of γ-T3 and statin. 
Therefore, the downstream apoptotic pathway of ER stress mediated cell death is 
still unclear. 
 
Taken together, current research shows that γ-T3 synergistically enhances the 
anti-proliferative effect of statins on MM cells via mevalonate pathway, and 
promotes apoptosis via ER stress signal and intrinsic apoptosis pathway, in which 
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one the vital inducer could be caspase 3 (Fig. D). Overall, the combination of γ-T3 
and statins could be useful for MM therapy and functions in a complementary style. 
These findings suggest that a combination treatment may cause significant 
inhibition of cancer cell growth, which will help to overcome the resistance of MM to 
current chemotherapies. The distinct molecular targets of this combined therapy 
should be explored in further detail. 
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Fig. D Mechanism scheme of “γ-T3 + statins”. Bold arrows indicate each effects 
induced by γ-T3, statins, and γ-T3 + statins, respectively which have shown in this 
study. 
 
 
 
 
Caspase 9 
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